- Press Release -

Rockville, Md. The global ovarian cancer diagnostics market is set to grow from around US$ 638 Mn in 2017 to a little over US$ 966 Mn by 2022, an 8.7% CAGR that Fact.MR ties to rising awareness of symptoms and greater use of screening as a preventive step. Multi-purpose diagnostic tests are broadening what a single assay can detect, which is expected to lift adoption further.

Epithelial tumors account for the overwhelming share of diagnosis, CA125 leads by test type, and hospital-associated labs handle most of the testing. North America carries the largest revenue, while Asia Pacific excluding Japan is the fastest-growing region. The pace of change also raises a practical challenge, as device makers work to keep up with the steady stream of new tests emerging from cancer research.

Tumors, Tests and Settings

Diagnosis of epithelial tumors dominates the market, holding more than 90% share at over US$ 875 Mn. Among tests, CA125 is the mainstay at more than 40% of revenue, while HER2 testing is gaining ground at a 9.5% CAGR and BRCA testing remains prominent. Hospital-associated labs are the largest end user, accounting for close to US$ 300 Mn of revenue in 2017.

North America stays dominant, at nearly US$ 240 Mn in 2017 and growing at 8.7%, helped by strong cancer research networks across the United States and Canada. Europe posts relatively faster growth on robust healthcare infrastructure, reaching a little over US$ 315 Mn by 2022, and Asia Pacific excluding Japan grows quickest at 9.5%, approaching US$ 127 Mn by the end of the period.

Screening Widens the Funnel

The market's momentum rests on earlier detection. As awareness of ovarian cancer symptoms rises and screening becomes more routine, more patients enter the diagnostic pathway, and multi-purpose tests make each encounter more productive. That combination is expected to sustain demand well through the forecast period.

Suppliers and Their Playbook

The field brings together diagnostics majors, sequencing specialists and pharmaceutical firms.

• Abbott Laboratories, Thermo Fischer Scientific Inc., Roche Holding AG, Siemens AG, Epigenomics AG, Bio-Rad Laboratories, Inc., Illumina, Inc., Myriad Genetics Inc., AstraZeneca plc. and Quest Diagnostics Incorporated are among the leading players in the report.

Reading the Market for Decisions

For diagnostics firms, CA125 volume and rising HER2 and BRCA testing mark where demand is heading. Investors get a market with a clear clinical tailwind and healthy growth. Procurement and lab teams can plan around hospital labs leading demand, epithelial tumor testing carrying revenue, and North America and APEJ offering the strongest prospects through 2022.

About the Report

Fact.MR's study covers the global ovarian cancer diagnostics market for the 2017 to 2022 forecast period, with segmentation by tumor type, test type, end user and region. It sizes each segment, maps the competitive field, and weighs the clinical and awareness forces shaping demand. Further detail is available in the ovarian cancer diagnostics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.